Prevalence and outcomes of DKA in type 1 and type 2 DM patients treated and not treated with SGLT ‐2 inhibitors

Documenti analoghi

• Associations between impaired awareness of hypoglycaemia and mental health in insulin‐treated type 2 and type 1 diabetes in the Hypo‐ METRICS study
  di: Aisling McCarthy, et al.
  Pubblicazione: (2026)
• Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population
  di: Ashish Rai, et al.
  Pubblicazione: (2026)
• Frequency of hypoglycaemia with basal insulin treatments in adults with type 1 diabetes treated with basal‐bolus insulin regimens in treat‐to‐target trials: A narrative review
  di: David Russell‐Jones, et al.
  Pubblicazione: (2024)
• Clinical effects of SGLT2 inhibitors in seven persons with HNF1A‐MODY (MODY3)
  di: Henrik Maagensen, et al.
  Pubblicazione: (2024)
• Clinical characteristics and outcomes of diabetes‐related ketoacidosis ( DKA ) in sodium‐glucose co‐transporter‐2 inhibitor ( SGLT2i ) users with type 2 diabetes
  di: Angelica Sharma, et al.
  Pubblicazione: (2025)